A Multicentre, Two Stage, Randomised, Double Blind Study of the Safety, Tolerability and Immunogenicity of a Human Immunodeficiency Virus (HIV) Vaccine Candidate, HIV-v.

Trial Profile

A Multicentre, Two Stage, Randomised, Double Blind Study of the Safety, Tolerability and Immunogenicity of a Human Immunodeficiency Virus (HIV) Vaccine Candidate, HIV-v.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2013

At a glance

  • Drugs HIV vaccine (Primary) ; Montanide ISA-51
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors SEEK
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Oct 2013 Phase Ib results published in Vaccine.
    • 18 Jul 2011 Results will be presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, according to a SEEK media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top